menu

NEWS

NeuroKaire Receives Clinical Laboratory Improvement Amendments Certification 

Comprehensive pharmacogenetic assay focused on psychiatry and neurology advances precision medicine for the brain. November 20, 2024 // PR Newswire NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, announced today that its Kearny, NJ-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.   NeuroKaire’s new CLIA laboratory’s first offering is a pharmacogenetic assay focused on psychiatric and neurological drugs. Pharmacogenetics is the study of the interaction between genetic variations and drug response. The comprehensive test analyzes 95 variants...

READ MORE
GEHA MENTAL HEALTH CENTER AND GENETIKA+ PARTNER ON NOVEL SOLUTIONS DRIVING PRECISION MEDICINE IN DEPRESSION

Geha Mental Health Center of Clalit Health Services and Genetika+ form a partnership to further develop and validate NeuroKaire for depression – a precision medicine tool combining stem-cell technology and AI for optimizing antidepressant choice TEL AVIV, March 11, 2024 The Research Authority of Geha Mental Health Center, Clalit Health Services, and Genetika+, a pioneer in precision medicine in the fields of psychiatry and neurology, are partnering to advance the development of tools to personalize depression treatment using stem-cell technology, Artificial Intelligence (AI) and advanced analytics. The collaboration between Genetika+ and Geha Mental Health Center is focused on the use of advanced...

READ MORE
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer’s Disease

Apr 22, 2024, 08:30 ET CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s state-of-the-art technology that derives frontal cortex neurons from individual patients’ blood to quantify drug-induced neuronal plasticity in vitro. The Genetika+ technology serves as a human AD disease model and will be used to correlate clinical response with cellular effects, for mechanistic drug insights and...

READ MORE
Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression March 6, 2024 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature. The study evaluated miR-Blood, Hummingbird Diagnostics’ small RNA expression dataset for eleven major components of human peripheral blood. A highly comprehensive blood cell type expression atlas for small RNAs, miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression, enabling a deeper understanding of blood and immune...

READ MORE
Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer’s Disease Biomarker Research at CTAD Conference

October 25, 2023 07:30 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in blood-based small RNA detection and characterization, today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer’s Disease (CTAD)conference in Boston. “Our mirCator platform sets new standards for blood-based small RNA handling, processing, analysis, and characterization”Tweet this The company has applied its state-of-the-art “mirCator” platform to answer critical questions related to Alzheimer’s disease. AI-powered mirCator provides deep insights through the integrated analysis of both disease & immune system derived small RNAs that was initially deployed for early detection of lung cancer (published...

READ MORE
Lung Cancer Data Heralds Shift for Hummingbird Diagnostics to Focus on Early Detection

Aug 01, 2023 | Molika Ashford genomeweb NEW YORK – German RNA-based testing firm Hummingbird Diagnostics is making strides to develop a microRNA assay for the early detection of lung cancer. Last month, the company published promising data on the development of an 18-miRNA signature dubbed miLung in the Journal of Thoracic Oncology. Hummingbird CSO Bruno Steinkraus said that the firm is very focused on early detection, even though its first foray into diagnostics was the development of a cancer immunotherapy response predictor.  “The [immunotherapy application] was more of a side project, but it was significantly easier to do,” he said. “With early detection, there...

READ MORE
1 2 3 9
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER